AMGEN INC
Government Contracts & Awards
AMGEN USA INC: TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MA
$773,879,007Proprietary Tech & Patents
DOWNSTREAM PROCESSING OF BISPECIFIC ANTIBODY CONSTRUCTS
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients
Will this pharma company become a new leader in the weight loss market?
Amgen Disagrees With FDA Proposal To Withdraw TAVNEOS From U.S. Market; Submitted Data And Analyses To FDA To Request Hearing On TAVNEOS
https://www.amgen.com/newsroom/company-statements/amgen-statement-on-fda-data-submission-for-tavneos?_gl=1*p4mfe*_up*MQ..*_ga*MjAxMjQ2Mjc4My4xNzg0ODk1MTYx*_ga_CBMSV0J9VL*czE3ODQ4OTUxNjEkbzEkZzEkdDE3ODQ4OTUxODMkajM4JGwwJG
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
Looking back on therapeutics stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers.
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
Amgen (AMGN) concluded the recent trading session at $371.47, signifying a +1.48% move from its prior day's close.
Amgen Inc (NASDAQ:AMGN) Shows Technical Strength and Breakout Setup
Amgen (AMGN) shows strong technical health with a 7/10 rating and a high-quality 9/10 setup pattern, signaling a potential breakout from consolidation near support.
Colorado Enbrel Price Cap Setback Might Change The Case For Investing In Amgen (AMGN)
Earlier in July, a federal judge blocked Colorado’s plan to impose a 70% price cap on Amgen’s blockbuster arthritis drug Enbrel, halting a significant state-level pricing move. The ruling eased concerns that aggressive state pricing limits on Enbrel could spread more widely, reducing a key regulatory overhang for Amgen’s portfolio. We’ll now explore how this legal setback to Colorado’s price cap effort could influence Amgen’s investment narrative and perceived long-term risks. Find 47...
Amgen (AMGN) Clears An Enbrel Overhang, Is The Stock Fully Priced?
A recent court decision blocking Colorado’s planned 70% price cap on Enbrel has removed a key regulatory overhang for Amgen (AMGN) and is refocusing attention on the stock’s earnings setup. See our latest analysis for Amgen. Beyond the court ruling, Amgen’s share price has quietly built positive momentum, with a 30 day share price return of 8.48% and year to date share price return of 11.78%, while the 1 year total shareholder return of 23.41% and 3 year total shareholder return of 70.66%...
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.3% on an annualized basis producing an average annual return of 13.64%. Currently, Amgen has a market capitalization of $197.77 billion.
Amgen Earnings Preview: What to Expect
Amgen is set to report Q2 earnings next month, with analysts expecting a single digit EPS decline.
Amgen or Biogen: Which Biotech Stock Appears Better Poised?
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.
Congressional Trades in $AMGN
Insider Trades (Form 4)
Bradner James E.
Bradway Robert A
Busch Matthew C.
Gordon Murdo
Graham Jonathan P
Griffith Peter H.
Grygiel Nancy A.
Khosla Rachna
Key People
REESE DAVID M
EVP & Chief Technology Officer
Miller Derek
SVP, Human Resources
Santos Esteban
EVP, Operations
Griffith Peter H
EVP & CFO
Khosla Rachna
SVP, Business Development
Busch Matthew C
VP, Finance & CAO
Graham Jonathan P
EVP & Gen. Counsel & Sec.
Gordon Murdo
EVP, Global Commercial Ops
Bradway Robert A
Chairman, CEO and President
Bradner James E
EVP, Research and Development
Grygiel Nancy A
SVP & CCO
ISHRAK OMAR
Director
Drake Michael V
Director
HOLLEY CHARLES M
Director
Political Giving
$428,000 given to 76 candidates across 223 disclosed contributions (FEC Schedule A).
Earl Leroy Carter
Scott H. Peters
Darin McKay LaHood
Adrian Smith
Carol Devine Miller
Terri A. Sewell
Nanette Barragan
Linda T. Sanchez
Katherine M. Clark
Bill Hagerty
Bradley S. Schneider
Kevin Hern
John Curtis
Shelley Moore Capito
Blake Moore
James E Hon Banks
Thomas H. Kean
Suzan K. DelBene
Rudy C. Yakym
August Lee Pfluger
+ 56 more recipients not shown.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro